Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 57 Kidney Neoplasms 16 Neoplasms 15 Neoplasm Metastasis 10 Carcinoma, Non-Small-Cell Lung 10 Colorectal Neoplasms 8 Carcinoma, Hepatocellular 8 Melanoma 7 Carcinoma 6 Glioblastoma 5 Clear-cell metastatic renal cell carcinoma 5 Lung Neoplasms 4 Uterine Cervical Neoplasms 3 Recurrence 3 Ovarian Neoplasms 3 Endometrial Neoplasms 3 Thyroid Neoplasms 2 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Skin Neoplasms 2 Sarcoma 2 Pheochromocytoma 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Paraganglioma 2 Liver Neoplasms 2 Kidney Diseases 2 Carcinoma, Adenoid Cystic 2 Breast Neoplasms 2 Advanced Solid Tumors 2 cT2a N0NxM0 Renal Tumor 1

Interventions

Pemetrexed 14 Carboplatin 13 osimertinib 10 aflutinib 9 Drug Therapy 9 Gefitinib 7 Radiotherapy 6 Docetaxel 6 Cisplatin 6 anlotinib 5 Radiosurgery 5 Paclitaxel 5 pembrolizumab 4 Vinorelbine 4 Gemcitabine 4 tislelizumab 3 icotinib 3 apatinib 3 HM781-36B 3 Erlotinib Hydrochloride 3 toripalimab 2 spartalizumab 2 rezivertinib 2 camrelizumab 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Immune Checkpoint Inhibitors 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × NSCLC × Axitinib × Clear all

NCT06020352 2023-08-31

The Efficacy and Safety of KN046 Combined With Axitinib

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2/3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡